Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.
Alterity Therapeutics announced the filing of its Annual Report on Form 20-F with the SEC, including audited financial statements for the year ending June 30, 2025. This filing, along with the XBRL interactive data, is available on their website, reflecting the company’s commitment to transparency and regulatory compliance, which could bolster stakeholder confidence and enhance its industry positioning.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has demonstrated efficacy in its lead asset, ATH434, through clinical trials for Multiple System Atrophy (MSA), and it operates from Melbourne, Australia, and San Francisco, USA.
YTD Price Performance: 40.0%
Average Trading Volume: 13,444,263
Technical Sentiment Signal: Sell
Current Market Cap: A$128.9M
See more insights into ATH stock on TipRanks’ Stock Analysis page.